Also known as: Trimeprazine

Active ingredient description

Alimemazine has a central sedative effect, comparable to that of chlorpromazine, but largely devoid of the latter’s antiadrenaline action. It has powerful antihistamine and anti-emetic actions. Alimemazine is used to treat neurosis, depression and anxiety of different origins. It prevents and relieves allergic conditions, which cause pruritus and urticaria by blocking histamine produced by the body during an allergic reaction. Alimemazine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use → R06AD Phenothiazine derivatives
Discover more medicines within R06AD01

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Summary of Product Characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₁₈H₂₂N₂S
Molecular mass: 298.446 g/mol

External identifiers

CAS Substance: 84-96-8
DrugBank Drug: DB01246
KEGG Drug: D07125
PubChem Compound: 5574
RxNorm Ingredient: 10825
SNOMED-CT Concept: 387471006
Alimemazine (substance)
UNII Identifier: 76H78MJJ52


Alimemazine is an active ingredient of these brands:

Canada (CA)

France (FR)

Malta (MT)

Spain (ES)

United Kingdom (UK)

While we strive to include the brand names of medicines across all countries, our index remains incomplete. Therefore, it is possible that this medicine may also be marketed under different names in other countries.